Andrew J. Wagner, MD, PhD

Associate Professor, Medicine, Harvard Medical School
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Andrew J Wagner, MD, PhD, is the Deputy Chief Medical Officer at Dana-Farber Cancer Institute and the Medical Director of Adult Ambulatory Oncology. In addition, he is a medical oncologist and translational researcher in the Center for Sarcoma and Bone Oncology and Associate Professor of Medicine at Harvard Medical School.

Poster(s):

• (P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION

• (P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN

• (P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA

• (P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY

• (P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS